|
NICE backs Roche’s MabThera in rare autoimmune disease
PMLiVE The draft guidance overturns an earlier decision made by NICE which failed to recommend the use of MabThera (rituximab) for NHS use in England and Wales to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis – an inflammation of the … Roche’s MabThera now favoured by NICE in vasculitisPharmaTimes |
Proactive Investors Australia |
Cellmid’s midkine antibodies show effectiveness against cancer
Proactive Investors Australia “We have postulated for some time that MK antibodies would have anti-cancer activities, via multiple mechanisms of action, and it is pleasing to see this confirmed in our own studies with our proprietary MK antibodies.” Cellmid’s cancer antibody … |
|
Researchers at Department of Haematology and Oncology Report Findings in …
HispanicBusiness.com Their experience showed that this drug is effective and manageable even when reused in both settings: chronic lymphocytic leukemia and non-Hodgkin’s lymphomas combined with rituximab and/or mitoxantrone. The slow evolution in the treatment of patients … |
Study Findings from Shanghai Jiao-Tong University Provide New Insights into …HispanicBusiness.comThe effect of rituximab alone or combined with the PI3K/AKT/mTOR pathway inhibitor rapamycin was further evaluated in the DLBCL cell lines. A total of 73…
|
New Lymphoma Study Findings Recently Were Reported by Researchers at …
HispanicBusiness.com Twenty-four patients were enrolled prospectively and were treated with unlabeled rituximab 70 mg and a therapeutic activity (median 7.3 GBq) of I-131 –rituximab.” The news correspondents obtained a quote from the research from the Institute of … |
Studies from University of Pisa Reveal New Findings on LymphomaHispanicBusiness.comAmong different possible chemotherapeutic approaches, purine analogs, alone or in association with Rituximab, seem to be a valid therapeutic choice. Fifty SMZL patients …
FDA Product Safety NewsSCVNEWS.comMore informationDrug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituxima…
|
Studies from West Virginia University Have Provided New Information about …
HispanicBusiness.com The news reporters obtained a quote from the research from West Virginia University , “Randomized trials comparing the addition (or not) of rituximab to high-dose therapy regimens are lacking. No benefit of standard-dose radio-immunotherapy-based … |
Laboratory Equipment |
Reagent Kits Deliver Probes, Antibodies into Cells
Laboratory Equipment PerFix-Expose and PerFix-nc, reagent kits for intracellular staining from Beckman Coulter Life Sciences, minimize sample manipulation for a streamlined workflow that delivers high-quality results. Developed for use on the company’s Gallios and Navios … |
|
3 Stocks to Buy When Your Government Shuts Down
DailyFinance Biogen continues to invest in multiple sclerosis, with a late-stage study under way for daclizumab and regulatory filings already submitted for Plegridy. However, Biogen’s pipeline holds promise in other areas as well. It awaits approval for drugs that … |